-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Zentalis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
- Zentalis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$88.3M, a 21.6% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$195M, a 31.7% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$292M, a 23.4% decline from 2022.
- Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$237M, a 49.2% decline from 2021.
- Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$159M, a 34.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)